{"id":"NCT02847637","sponsor":"Hoffmann-La Roche","briefTitle":"A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors","officialTitle":"A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients Without Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-27","primaryCompletion":"2017-09-15","completion":"2022-05-12","firstPosted":"2016-07-28","resultsPosted":"2018-11-14","lastUpdate":"2022-11-16"},"enrollment":152,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A"],"interventions":[{"type":"DRUG","name":"Emicizumab","otherNames":["Hemlibra","RO5534262","ACE910"]},{"type":"DRUG","name":"Factor VIII (FVIII)","otherNames":[]}],"arms":[{"label":"Arm C (Control): No Prophylaxis, Then Emicizumab","type":"ACTIVE_COMPARATOR"},{"label":"Arm A: Emicizumab 1.5 mg/kg QW","type":"EXPERIMENTAL"},{"label":"Arm B: Emicizumab 3 mg/kg Q2W","type":"EXPERIMENTAL"},{"label":"Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)","type":"EXPERIMENTAL"}],"summary":"This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.","primaryOutcome":{"measure":"Annualized Bleeding Rate (ABR) for Treated Bleeds","timeFrame":"From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)","effectByArm":[{"arm":"Arm C (Control): No Prophylaxis","deltaMin":38.2,"sd":null},{"arm":"Arm A: Emicizumab 1.5 mg/kg QW","deltaMin":1.5,"sd":null},{"arm":"Arm B: Emicizumab 3 mg/kg Q2W","deltaMin":1.3,"sd":null},{"arm":"Arm D: Emicizumab 1.5 mg/kg QW (Pre-study FVIII Prophylaxis)","deltaMin":1.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":11},"locations":{"siteCount":39,"countries":["United States","Australia","Costa Rica","France","Germany","Ireland","Italy","Japan","Poland","South Africa","South Korea","Spain","Taiwan","United Kingdom"]},"refs":{"pmids":["35939785","35905294","30157389"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":18},"commonTop":["ARTHRALGIA","INJECTION SITE REACTION","NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","HEADACHE"]}}